FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 604 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer MOST POPULAR Sister Is There To Comfort Her Little Brother As He Battles... September 10, 2019 EMA Recommends Extension of Therapeutic Indications for Ibrutinib July 15, 2022 EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... April 3, 2025 EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan November 14, 2022 Load more HOT NEWS All in the Family – A Story about Genetics and Breast... FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy...
